PolyPid misses EPS consensus as November FDA decision nears

By Tom Whitfield

What do earnings and cash show?

PolyPid Ltd. (NASDAQ: PYPD) reported a loss of $0.24 per share for the quarter, missing the $0.91 analyst consensus by $1.15, according to FiscalAI. The company announced the result Wednesday.

The business ended the quarter with $15.5 million in cash and short-term deposits and received another $15 million from Azurity in early October. Management expects those resources to fund operations into 2028, although the company did not provide a cash-burn forecast or explain the pace of spending after the October payment.

Takeaway: The cash position extends the stated runway, but no forecast allows investors to test that promise.

What happens at the FDA on November 28?

D-PLEX100 has a Nov. 28 priority-review PDUFA date, the target date for FDA action. The company is discussing labeling, and management described scheduled FDA interactions as “on track.” Neither approval nor the planned early-2027 launch is assured; both depend on FDA action. Management did not discuss inspection details, leaving that part of the regulatory process outside the reported discussion.

PolyPid also plans to begin FDA discussions this quarter about expanding D-PLEX100 beyond colorectal surgery into broader abdominal procedures. The agency has not yet told the company what evidence or requirements it would demand, so the expansion remains an option rather than an agreed development path.

Takeaway: Nov. 28 sets the next FDA decision date, but neither the label nor the broader abdominal indication is settled.

Can the U.S. launch follow approval?

A possible early-2027 U.S. launch still faces an account-by-account adoption process. PolyPid and Azurity are preparing, with Azurity building commercial teams and targeting hospitals. Management cautioned that formulary reviews occur account by account and adoption may take several months, leaving hospital access subject to a sequence of individual reviews.

A CMS decision on New Technology Add-on Program, or NTAP, reimbursement is expected in August 2027. That date falls after the planned early-2027 launch, and management did not quantify any effect on hospital uptake.

Takeaway: The launch window and reimbursement timetable remain separate, and neither guarantees rapid hospital adoption.

What changed in Europe and the pipeline?

A second regulatory decision could arrive in the second half of 2027. The EMA validated PolyPid’s D-PLEX100 application and began its review, with a decision expected in that period.

Separately, PolyPid ended its European agreement with ADVANZ PHARMA, regained commercialization rights and said it is discussing potential partnerships. The company disclosed no new partner or commercial terms, so the restored rights do not establish a functioning European sales channel.

PolyPid plans a PD01B pre-IND meeting and a first-in-human study in the second half of 2027. PD01B remains in development, and the company disclosed no trial design, cost or enrollment timetable.

Takeaway: Europe offers a second regulatory route, while PD01B remains several steps behind a clinical study.

How did shares and analyst research react?

PYPD rose $0.30 during Wednesday trading to $6.62. Trading volume reached 359,090 shares, compared with an average of 125,961. The stock carried a market capitalization of $126.21 million, a P/E ratio of -4.47 and a beta of 1.43.

Its one-year range ran from $3.50 to $7.15. The 50-day moving average stood at $5.30, and the 200-day moving average stood at $4.77. Those measures describe trading history; they do not resolve the regulatory and commercialization questions ahead.

Published analyst positions remain split:

• HC Wainwright reiterated a “buy” rating and set a $13.00 price target on Tuesday, July 21.
• Weiss Ratings restated a “sell (d-)” rating on Friday, September 18.
• Oppenheimer began coverage on Tuesday, October 27, with an “outperform” rating and a $10.00 price objective.
• Craig Hallum set a $12.00 price target on Wednesday, July 22; the summary did not specify a rating.
• Wall Street Zen upgraded the shares from “hold” to “buy” on Saturday, October 31.

MarketBeat counts four analysts at Buy and one at Sell. Its consensus rating is “Moderate Buy,” with an average price target of $11.00. That average reflects published forecasts rather than a settled outcome for D-PLEX100.

Takeaway: The “Moderate Buy” consensus masks disagreement among published research and leaves the core execution questions unresolved.

What is PolyPid trying to build?

PolyPid describes itself as a clinical-stage biopharmaceutical company developing locally administered therapies designed to release drugs in a controlled, sustained manner at treatment sites. The technology aims to maintain therapeutic concentrations for longer while limiting systemic exposure, a design that would matter if treatment-site levels prove effective and systemic levels remain low.

Its lead candidate, the investigational D-PLEX100, combines doxycycline with PolyPid’s proprietary PLEX polymeric matrix. The company is developing it to prevent surgical-site infections, initially in patients undergoing colorectal surgery. The November FDA decision therefore tests both the product’s regulatory viability and the commercial model built around local treatment.

Takeaway: The technology has a defined medical purpose, but approval and broad hospital adoption remain unproven.